The mobile payment terminal supplier booked $5.8m from its IPO and is now lining up an acquisition to expand its business.

Cancer therapy developer Oric, whose backers include Memorial Sloan, Taiho and Hartford HealthCare, floated at the top of its range in an expanded IPO.

BAIC has notched up an exit after the aluminium alloy component provider went public in a $47.8m offering on the Shenzhen Stock Exchange.

Partners Healthcare and Medison Pharma-backed Keros Therapeutics floated at the top of its range and will look to advance its musculoskeletal disorder drug candidates.

The Pharamron-backed oncology drug developer floated at the top of its range while increasing the number of shares in the offering.

Pfizer and Lundbeck scored exits as blood-disease therapy developer Imara raised $75.2m, floating at the foot of its range.

The genetic therapy developer, which had raised $126m in funding from investors including Eli Lilly and Access Industries, added $32.4m to the offering.

Underwriters have exercised their over-allotment option in full, increasing the University of Pennsylvania-linked genetic medicine developer’s proceeds by $32.4m.

The UC Santa Barbara-founded semiconductor technology producer has gone public through a reverse merger with penny stock company Peninsula Acquisition and received $21.5m from investors including Marelli.

Chinese Academy of Sciences and its VC subsidiary TCL Capital are in line to exit the artificial intelligence chip producer, which was valued at $2.5bn as of 2018.